incompatible

不兼容
  • 文章类型: Journal Article
    最近在ABO不相容(ABOi)心脏移植中引入了术中抗A/B免疫吸附(ABO-IA)。在这里,我们报告了第一例ABO-IA移植的患者,需要两个ABO-IA柱平行运行的年龄和体重,能够在移植供体器官期间的可用时间内将抗体滴度降低到足够低的水平。
    Intraoperative anti-A/B immunoadsorption (ABO-IA) was recently introduced for ABO-incompatible (ABOi) heart transplantation. Here we report the first case of a patient transplanted with ABO-IA, that was of an age and weight that required two ABO-IA columns run in parallel, to enable the reduction in antibody titres to a sufficiently low level in the time available during implantation of the donor organ.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    引入含有潜在ABO不相容血浆的低滴度O组全血(LTOWB),以及增加使用A组血浆,由于AB等离子体的短缺,在ABO组未知的创伤患者中,不相容血浆受体有增加发病率和死亡率的风险.这项研究评估了接受不相容血浆后的平民创伤患者的预后。
    分析了一个创伤中心的患者对三项不同创伤复苏策略的多中心研究的贡献;根据仅接受相容血浆与接受任何量的不相容血浆,将这些患者分为两组。进行多变量分析以确定接受不相容血浆是否与24小时或30天死亡率相关。
    有347名患者符合此二次分析的条件,其中167名仅接受相容血浆,180名接受不相容血浆。两组在人口统计上以及院前和医院到达的生命体征上都很匹配。这些患者接受的不相容血浆的中位数(IQR)体积为684ml(342,1229)。两组在24小时和30天死亡率方面没有显着差异,也没有在医院或重症监护病房住院时间。在24小时和30天生存的Cox比例风险回归模型中,接受不相容血浆不能独立预测任一死亡终点.
    接受不相容血浆与创伤患者死亡率增加并不独立相关。需要前瞻性研究来证实这些发现。
    UNASSIGNED: The introduction of low titer group O whole blood (LTOWB) that contains potentially ABO-incompatible plasma and the increasing use of group A plasma, due to shortages of AB plasma, in trauma patients whose ABO group is unknown could put the recipients of incompatible plasma at risk of increased morbidity and mortality. This study evaluated civilian trauma patient outcomes following receipt of incompatible plasma.
    UNASSIGNED: One trauma center\'s patient contributions to three multicenter studies of different trauma resuscitation strategies was analyzed; these patients were separated into two groups based on receipt of only compatible plasma versus receipt of any quantity of incompatible plasma. Multivariate analysis was performed to determine if receipt of incompatible plasma was associated with 24-hour or 30-day mortality.
    UNASSIGNED: There were 347 patients eligible for this secondary analysis with 167 recipients of only compatible plasma and 180 recipients of incompatible plasma. The two groups were well matched demographically and on both prehospital and hospital arrival vital signs. The median (IQR) volume of incompatible plasma received by these patients was 684 ml (342, 1229). There was not a significant difference between the groups in 24-hour and 30-day mortality, nor in in-hospital or intensive care unit lengths of stay. In the Cox proportional-hazards regression model for both 24-hour and 30-day survival, receipt of incompatible plasma was not independently predictive of either mortality endpoint.
    UNASSIGNED: Receipt of incompatible plasma was not independently associated with increased mortality in trauma patients. Prospective studies are needed to confirm these findings.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Systematic Review
    这个准则,来自欧洲器官移植学会(ESOT)工作组,与HLA抗体肾移植患者的管理有关.应使用虚拟参数定义敏化,如计算出的反应频率(cRF)、评估来自实际器官供体群体的HLA抗体。高度致敏的患者应优先考虑肾脏分配方案,而链接分配方案可能会增加机会。ENGAGE5的使用((Bestard等人,TransplInt,2021,34:1005-1018)推荐用于评估风险的系统和在线计算器。欧洲移植可接受的不匹配计划应该延长。如果寻找相容肾脏的策略不太可能进行移植,脱敏可以考虑,应该进行血浆置换或免疫吸附,补充有IViG和/或抗CD20抗体。较新的疗法,如imlifidase,可以提供替代方案。很少有研究将HLA不相容移植与保留在等待名单上进行比较,和发病率或生活质量的比较不存在。肾脏配对交换计划(KEP)应更广泛地使用,并应包括未指定和已故的捐赠者,以及相容的活体捐赠者对。使用KEP优于脱敏,但如果存在直接不相容移植的选择,高度致敏的患者不应无限期留在KEP名单上.
    This guideline, from a European Society of Organ Transplantation (ESOT) working group, concerns the management of kidney transplant patients with HLA antibodies. Sensitization should be defined using a virtual parameter such as calculated Reaction Frequency (cRF), which assesses HLA antibodies derived from the actual organ donor population. Highly sensitized patients should be prioritized in kidney allocation schemes and linking allocation schemes may increase opportunities. The use of the ENGAGE 5 ((Bestard et al., Transpl Int, 2021, 34: 1005-1018) system and online calculators for assessing risk is recommended. The Eurotransplant Acceptable Mismatch program should be extended. If strategies for finding a compatible kidney are very unlikely to yield a transplant, desensitization may be considered and should be performed with plasma exchange or immunoadsorption, supplemented with IViG and/or anti-CD20 antibody. Newer therapies, such as imlifidase, may offer alternatives. Few studies compare HLA incompatible transplantation with remaining on the waiting list, and comparisons of morbidity or quality of life do not exist. Kidney paired exchange programs (KEP) should be more widely used and should include unspecified and deceased donors, as well as compatible living donor pairs. The use of a KEP is preferred to desensitization, but highly sensitized patients should not be left on a KEP list indefinitely if the option of a direct incompatible transplant exists.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    越来越多的文献证明了院前和早期院内输血的益处。RhD阳性产品可能仅在这些阶段可用,如果发生D-同种免疫,可能会对未来的怀孕造成影响。这项调查根据未来妊娠并发症的可能性,测量了女性接受紧急但不相容输血的意愿。
    一项调查旨在评估≥18岁的女性接受紧急不相容输血的意愿,当产妇死亡率的绝对风险降低不同时,对未来怀孕的伤害风险静态率为0.3%-4.0%。该调查以电子方式发送给华盛顿大学研究增强核心数据库中的女性。
    共分发了4896份已发送的调查电子邮件邀请,收到325份(6.6%)回复;16份回复被排除,留下309份回复供分析。大多数回应的女性是白人,受过大学教育,住在密苏里州。当孕产妇死亡率的绝对风险降低≥4%时,至少90%的受访者会接受紧急不相容输血。没有大学学位的女人,他住在伊利诺伊州,当孕产妇死亡率的绝对风险降低较低时,那些无法生育孩子的人似乎比他们的同龄人更不愿意接受不相容的输血。
    这项调查表明,当产妇死亡率的绝对风险降低≥4%时,在出血紧急情况下,成年女性很可能愿意接受紧急不相容输血。
    There is an increasing literature demonstrating the benefits of prehospital and early in-hospital transfusions. RhD-positive products might only be available during these phases, which could pose consequences for future pregnancies if D-alloimmunization occurs. This survey measured the willingness of females to accept urgent but incompatible transfusions in light of the potential for future pregnancy complications.
    A survey was designed to assess the willingness of females ≥18 years of age to accept urgent incompatible transfusions when different absolute risk reductions in maternal mortality were presented along with a static rate of 0.3%-4.0% risk of harm to future pregnancies. The survey was sent electronically to women who are part of the Washington University Research Enhancement Core database.
    A total of 4896 delivered survey email invitations were distributed and 325 (6.6%) responses were received; 16 responses were excluded leaving 309 responses for analysis. Most of the responding women were White, college-educated, and lived in Missouri. At least 90% of the respondents would accept an urgent incompatible transfusion when the absolute risk reduction in maternal mortality was ≥4%. Women without a college degree, who lived in Illinois, who were not able to have children appeared to be less willing than their counterparts to receive an incompatible transfusion when the absolute risk reduction in maternal mortality was low.
    This survey demonstrated that adult women are highly likely to be open to accept urgent incompatible blood transfusions during a bleeding emergency when the absolute risk reduction in maternal mortality was ≥4%.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    晚疫病是限制马铃薯产量的主要生物胁迫之一;然而,致病疫霉感染过程的生化机制仍未揭示。在这项研究中,在抗晚疫病马铃薯品种紫云1号(R)和易感品种Favorita(S)上接种了疫霉。非靶向代谢组学用于研究两个品种与病原体在接种后0、48和96小时(hpi)的相容和不相容相互作用中代谢物的变化。共鉴定出819种代谢物,代谢差异主要出现在48hpi后。在相容和不相容的相互作用中,有198和115种差异表达的代谢物(DEM)。这些包括在相容和不相容相互作用期间的147和100个上调的代谢物,分别。其中,73种代谢物被鉴定为致病疫霉响应性DEM。此外,两个品种之间的比较确定了57种与抗性相关的代谢物。抗性马铃薯品种具有较高水平的水杨酸和几种上游苯丙素生物合成代谢产物,三萜类,和羟基肉桂酸及其衍生物,如Sakuranetin,阿魏酸,灵芝酸Mi,葡萄糖酸D2和咖啡酰苹果酸。这些代谢物在细胞壁增厚中起着至关重要的作用,并具有抗菌和抗真菌活性。这项研究报告了马铃薯对致病假单胞菌的时程代谢组学反应。研究结果揭示了马铃薯和致病疫霉的相容和不相容相互作用所涉及的反应。
    Late blight is one of the main biological stresses limiting the potato yield; however, the biochemical mechanisms underlying the infection process of Phytophthora infestans remain unrevealed. In this study, the late blight-resistant potato cultivar Ziyun No.1 (R) and the susceptible cultivar Favorita (S) were inoculated with P. infestans. Untargeted metabolomics was used to study the changes of metabolites in the compatible and incompatible interactions of the two cultivars and the pathogen at 0, 48, and 96 h postinoculation (hpi). A total of 819 metabolites were identified, and the metabolic differences mainly emerged after 48 hpi. There were 198 and 115 differentially expressed metabolites (DEMs) in the compatible and incompatible interactions. These included 147 and 100 upregulated metabolites during the compatible and incompatible interactions, respectively. Among them, 73 metabolites were identified as the P. infestans-responsive DEMs. Furthermore, the comparisons between the two cultivars identified 57 resistance-related metabolites. Resistant potato cultivar had higher levels of salicylic acid and several upstream phenylpropanoid biosynthesis metabolites, triterpenoids, and hydroxycinnamic acids and their derivatives, such as sakuranetin, ferulic acid, ganoderic acid Mi, lucidenic acid D2, and caffeoylmalic acid. These metabolites play crucial roles in cell wall thickening and have antibacterial and antifungal activities. This study reports the time-course metabolomic responses of potatoes to P. infestans. The findings reveal the responses involved in the compatible and incompatible interactions of potatoes and P. infestans.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    与持续透析相比,人类白细胞抗原(HLA)不相容的肾脏移植具有生存益处。在过去的十年中,已经取得了相当大的进步,以允许HLA致敏的肾移植候选者获得更多的移植机会。这些包括增加肾脏分配系统的优先级,肾脏配对捐赠,和新颖的脱敏策略。更好地了解B细胞的作用,浆细胞,补体和炎性细胞因子在HLA抗体介导的同种异体移植损伤的病理生理学中的应用已经导致新的疗法用于脱敏和治疗抗体介导的排斥反应。在这里,我们讨论了HLA致敏的肾移植候选人中肾移植的当前方法。
    Human leukocyte antigen (HLA)-incompatible kidney transplantation offers survival benefit compared with ongoing dialysis. There have been considerable advances in the last decade to allow for increased access to transplant for the HLA-sensitized kidney transplant candidates. These include increased priority in the kidney allocation system, kidney paired donation, and novel desensitization strategies. A better understanding of the role of B cells, plasma cells, and complement and inflammatory cytokines in the pathophysiology of HLA antibody-mediated allograft injury has led to the use of novel therapeutics for desensitization and treatment of antibody-mediated rejection. Here we discuss current approaches to kidney transplantation in HLA-sensitized kidney transplant candidates.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Rh(D)-不相容(Rh-i)实体器官移植不考虑器官匹配,但关于抗D免疫球蛋白(RhIG)预防的必要性尚无共识指南.
    我们回顾了35例接受Rh-i实体器官移植的Rh(D)阴性患者。我们将患者分为RhIG给药组和未给药组。所有患者还接受了抗体筛选测试以评估Rh同种免疫。每当怀疑有排斥反应时,用血清肌酐或胆红素和肾脏或肝脏活检监测移植物功能。还评估了总生存率。
    移植受者的中位(范围)年龄为48.5(4-69)岁,73.5%的患者为男性。移植后中位(范围)随访时间为60(2-246)个月。在RhIG未给药组(n=16)中,在任何患者中均未检测到抗D.在接受肾移植的患者中,使用RhIG的组发生了更多的排斥反应(P=0.0278)。
    Rh(D)同种免疫的低比率与患者的免疫抑制状态有关。RhIG预防在Rh-i实体器官移植中似乎没有临床益处。
    Rh(D)-incompatible (Rh-i) solid organ transplantations are not considered for organ matching, but no consensus guidelines exist regarding the need for anti-D immunoglobulin (RhIG) prophylaxis.
    We reviewed 35 Rh(D)-negative patients who had received Rh-i solid organ transplantation. We divided the patients into a RhIG-administered group and a nonadministered group. All patients also underwent an antibody screening test to assess Rh alloimmunization. Graft function was monitored with serum creatinine or bilirubin and kidney or liver biopsy whenever a rejection was suspected. Overall survival was also assessed.
    The median (range) age of transplant recipients was 48.5 (4-69) years, and 73.5% of patients were male. Median (range) follow-up time after transplantation was 60 (2-246) months. In the RhIG nonadministered group (n = 16), anti-D was not detected in any of the patients. More rejection episodes occurred in the RhIG-administered group among those undergoing kidney transplant (P = .0278).
    The low rate of Rh(D) alloimmunization is associated with the immunosuppressive state of the patients. RhIG prophylaxis seems to have no clinical benefit in Rh-i solid organ transplantation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    The last several decades have seen significant changes in the approach to resuscitation of bleeding patients. These include the adoption of ABO-incompatible plasma transfusion in the form of group A plasma and/or low titer group O whole blood for trauma patients of unknown ABO group. Studies to date have examined the impact of these practices on patient outcomes and clinical markers of hemolysis in recipients of ABO-incompatible plasma compared to those for whom the plasma is ABO-compatible. Risk for increased mortality and/or overt hemolysis appear to be low among recipients of ABO-incompatible plasma; however, nearly all of studies are retrospective and most have focused only on adult trauma patients so results may not be generalizable to other bleeding patients. Work continues to evaluate the role of various titer thresholds in decreasing hemolytic risk and opportunities remain to improve our understanding of anti-A and anti-B antibody interactions with complement/endothelium and identify strategies to minimize risk.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    Site-isolation of catalysts can enable incompatible catalysts such as acid and base to be used in one pot for enhanced efficiency and other benefits. Although many synthetic platforms have been reported for this purpose, they generally do not possess the exquisite selectivity of site-isolated enzymes in nature. Here we report water-soluble protein-sized nanoparticles with site-isolated acids in the core and amines on the surface. The catalysts were made through molecular imprinting of cross-linked micelles, followed by facile one-step photoaffinity labeling of the imprinted binding site. With a tunable, substrate-specific active site, the bifunctional artificial enzyme catalyzed highly selective tandem cross aldol reaction between acetone and mixtures of isomeric aryl acetals. It could also transform a less reactive substrate over a more reactive one.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号